Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma
暂无分享,去创建一个
T. Liang | X. Bai | Haiyang Xie | Shusen Zheng | XueLi Bai | LiHua Wu | TingBo Liang | ZhiQiang Liu | JunJian Li | DongLin Li | HaiYang Xie | ShengYong Yin | Jun Yu | Qi Lin | ShuSen Zheng | Jun Yu | Lihua Wu | Donglin Li | Junjian Li | Zhi-qiang Liu | Shengyong Yin | Qiming Lin
[1] A Geerts,et al. History, Heterogeneity, Developmental Biology, and Functions of Quiescent Hepatic Stellate Cells , 2001, Seminars in liver disease.
[2] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[3] H. Huber,et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. , 2006, Oncogene.
[4] E. Olson,et al. MEF 2 : a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation , 1999 .
[5] M. Yeh,et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[6] N. L. La Thangue,et al. Histone deacetylase inhibitors open new doors in cancer therapy. , 2004, Biochemical pharmacology.
[7] J. Wen,et al. Enhancement of diallyl disulfide-induced apoptosis by inhibitors of MAPKs in human HepG2 hepatoma cells. , 2004, Biochemical pharmacology.
[8] Saeed Tavazoie,et al. Mapping Global Histone Acetylation Patterns to Gene Expression , 2004, Cell.
[9] W. Bickmore,et al. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? , 2005, EMBO reports.
[10] C. Bucana,et al. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. , 1997, Science.
[11] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[12] L. Mahadevan,et al. Enhanced histone acetylation and transcription: a dynamic perspective. , 2006, Molecular cell.
[13] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[14] S. Thung,et al. Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. , 2008, Liver.
[15] N. Fusenig,et al. Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.
[16] J. Bruix,et al. Treatment of hepatocellular carcinoma. , 2006, Critical reviews in oncology/hematology.
[17] S. Ferrari,et al. The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. , 2001, Journal of cell science.
[18] D. Gotley,et al. Evidence that "myofibroblast-like" cells are the cellular source of capsular collagen in hepatocellular carcinoma. , 1997, Journal of hepatology.
[19] S. Horvath,et al. Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.
[20] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[21] Eun-Joung Moon,et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes , 2001, Nature Medicine.
[22] M E Greenberg,et al. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. , 1999, Science.
[23] I. Witz,et al. The tumor microenvironment in the post-PAGET era. , 2006, Cancer letters.
[24] Jiuhong Kang,et al. Nickel-induced histone hypoacetylation: the role of reactive oxygen species. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.
[25] Carlos Caldas,et al. Chromatin modifier enzymes, the histone code and cancer. , 2005, European journal of cancer.
[26] Jiuhong Kang,et al. Involvement of histone hypoacetylation in Ni2+-induced bcl-2 down-regulation and human hepatoma cell apoptosis , 2004, JBIC Journal of Biological Inorganic Chemistry.
[27] T. Liang,et al. Activation pattern of mitogen‐activated protein kinases in early phase of different size liver isografts in rats , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[28] S. Archer,et al. Histone acetylation and cancer. , 1999, Current opinion in genetics & development.
[29] W. Mikulits,et al. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF‐β dependent fashion , 2006, Journal of cellular physiology.
[30] Jun O. Liu,et al. Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. , 2004, Journal of molecular biology.
[31] E. Olson,et al. Control of muscle development by dueling HATs and HDACs. , 2001, Current opinion in genetics & development.
[32] B. Black,et al. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. , 1998, Annual review of cell and developmental biology.
[33] Giulio Gabbiani,et al. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. , 2004, The International journal of developmental biology.
[34] H. Gruffat,et al. MEF2‐mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling , 2002, EMBO reports.
[35] Stuart L Schreiber,et al. Histone Deacetylase Activity Is Required for Full Transcriptional Repression by mSin3A , 1997, Cell.
[36] B. Howard,et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A , 1996, Nature.
[37] B. Black,et al. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor , 2002, Nature Medicine.
[38] Yufeng Shi,et al. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. , 2005, Biochemical pharmacology.
[39] Stefano Colagrande,et al. Fibrosis in chronic liver diseases: diagnosis and management. , 2005, Journal of hepatology.
[40] E. Cho,et al. Menin represses JunD transcriptional activity in protein kinase Cθ-mediated Nur77 expression , 2005, Experimental & Molecular Medicine.
[41] S. Friedman,et al. Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. , 2004, Gastroenterology.
[42] Tony Kouzarides,et al. Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.
[43] S. T. Kim,et al. Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression. , 2005, Experimental & molecular medicine.
[44] Zhenguo Wu,et al. Myocyte Enhancer Factor 2 Acetylation by p300 Enhances Its DNA Binding Activity, Transcriptional Activity, and Myogenic Differentiation , 2005, Molecular and Cellular Biology.
[45] Yufeng Shi,et al. Histone hypoacetylation is involved in 1,10-phenanthroline–Cu2+-induced human hepatoma cell apoptosis , 2005, JBIC Journal of Biological Inorganic Chemistry.
[46] Y. Tokusashi,et al. Expression of NGF in hepatocellular carcinoma cells with its receptors in non‐tumor cell components , 2005, International journal of cancer.